Novo Looks at Raising Obesity Sales Targets on Demand for Wegovy
(Bloomberg) -- Novo Nordisk A/S is considering raising the sales guidance for its obesity drugs after a strong introduction for its new medication called Wegovy, Chief Executive Officer Lars Fruergaard Jorgensen said in an interview.
“It's fair to say that the prospects here are better than we have guided,” Jorgenson said. “The clinical profile was better than we anticipated, the market reception is very strong, and we also see that even in markets without Wegovy that the obesity market is also being established.”
Novo has previously said it aims to more than double 2019 obesity sales by 2025, to about $1.8 billion. The company hasn't decided the specific new guidance yet and is waiting to see more data about Wegovy's performance and for supply of the drug to stabilize, Jorgensen said.
Read more: Drugmaker struggles to meet demand for weight-Loss med
Wegovy, which was approved by the U.S. Food and Drug Administration in June, helps patients lose about 15% of their body weight on average. Within about five weeks, the company saw as many prescriptions for Wegovy as Saxenda had produced in a few years, Jorgensen said.
“The initial number of scripts significantly outpaced our expectations, and then we ran into supply issues and we had to face a more flat-ish development in new scripts,” he said. “We had expected a more steady build, which is what we have seen in the past, when we have launched new products.”
Novo also makes the weight loss medication Saxenda, which was launched in the U.S. in 2015 and is expected to lose patent protection in the coming years. The space is seen as a key avenue of growth for Novo, which known primarily as a diabetes-drug maker.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.